|Day Low/High||88.26 / 90.52|
|52 Wk Low/High||86.55 / 147.17|
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
Celgene Corporation (NASDAQ:CELG) today announced that it has completed the acquisition of Juno Therapeutics, Inc.
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, Inc.
Nobody likes tariffs, says Jim Cramer. But Trump said he'd do it. Even so, trade and tariff fears have hit Wall Street -- and investors -- hard.
These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Jim Cramer questions whether Celgene overpaid in its $7.2 billion deal for Receptos.
The Food and Drug Administration determined that the nonclinical and clinical pharmacology sections in the new drug application "were insufficient to permit a complete review," Celgene said.
Celgene Corporation (NASDAQ:CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ozanimod in development...
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company.
Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by Celgene's...
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA ® (apremilast) in patients with active Behçet's Disease with oral ulcers were presented in a...
Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one...
Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors.
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
Celgene Corporation (NASDAQ: CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock.
Wow. Corporate America is sitting on massive amounts of cash that could be unleashed on deals, according to new research from Citi.
In this tape, weakness may just be a sign of rest and better times to come.
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.
A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.